# Dossier: GATEWAY BIOTECHNOLOGY, INC.

## SBIR Award Details

**Award Title:** N/A

**Amount:** $1,299,999.00

**Award Date:** 2023-09-18

**Branch:** DHA

## AI-Generated Intelligence Summary

**Company Overview:**

Gateway Biotechnology, Inc. is a preclinical-stage biopharmaceutical company focused on developing novel therapies to address unmet medical needs in wound healing, tissue regeneration, and infectious disease, with a particular emphasis on applications relevant to defense and aerospace. Their core mission is to develop and commercialize advanced peptide-based therapeutics that accelerate wound closure, reduce scarring, and combat antibiotic-resistant infections, ultimately improving outcomes for both civilian and military populations facing traumatic injuries and complex infections. Their unique value proposition lies in their proprietary peptide platform technology which allows for the design of targeted therapeutics that enhance the body's natural healing mechanisms and exhibit broad-spectrum antimicrobial activity while minimizing the risk of resistance development. They are particularly focused on developing solutions for burns, chronic wounds (like diabetic ulcers), and combat-related injuries.

**Technology Focus:**

* Peptide-Based Therapeutics:\*\* Gateway Biotechnology's core technology revolves around the design and synthesis of novel peptides with targeted biological activities. These peptides are engineered to promote angiogenesis, reduce inflammation, stimulate cell proliferation, and directly inhibit bacterial growth. They specifically engineer peptides that interact with specific receptors and signaling pathways involved in tissue repair and immune modulation.
* Broad-Spectrum Antimicrobial Peptides (AMPs):\*\* The company is developing a pipeline of AMPs designed to combat a wide range of bacterial pathogens, including multi-drug resistant strains. These peptides disrupt bacterial cell membranes and inhibit bacterial growth without relying on mechanisms that promote resistance. They report showing efficacy against several strains of Methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive and Gram-negative bacteria in preclinical studies.

**Recent Developments & Traction:**

* NIH Funding:\*\* In 2022, Gateway Biotechnology was awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Institutes of Health (NIH) to support the development of their antimicrobial peptide for the treatment of burn wound infections.
* Presentation at Scientific Conferences:\*\* The company has presented preclinical data at several scientific conferences in the past two years, showcasing the efficacy of their peptide therapeutics in wound healing and antimicrobial applications. This includes presentations related to in-vivo studies demonstrating accelerated wound closure and reduced scar formation.
* Partnership with Academic Institutions:\*\* Gateway Biotechnology maintains collaborative research agreements with several leading academic institutions to further validate their technology and explore new therapeutic applications. Details are scarce regarding exact partner names or project details.

**Leadership & Team:**

* While specific names were difficult to definitively confirm, web content and business records indicate that the company's leadership includes scientists with advanced degrees in biochemistry, molecular biology, and related fields. Details are limited and lack strong identifiable information.

**Competitive Landscape:**

* Regeneron Pharmaceuticals:\*\* Regeneron is a major player in the biopharmaceutical industry with a broad portfolio of therapeutics, including some focused on wound healing and inflammatory conditions. Gateway Biotechnology differentiates itself by focusing on a peptide-based approach, offering potential advantages in terms of targeted delivery, reduced toxicity, and lower development costs.
* Acelity (now part of 3M):\*\* Acelity, primarily known for its wound care products including negative pressure wound therapy (NPWT), represents competition in the broader wound care market. Gateway differentiates by offering a potentially more targeted and effective therapeutic intervention at the molecular level, rather than a device-based approach.

**Sources:**

* [https://www.zoominfo.com/c/gateway-biotechnology-inc/350302918](https://www.zoominfo.com/c/gateway-biotechnology-inc/350302918)
* [https://www.cbinsights.com/company/gateway-biotechnology](https://www.cbinsights.com/company/gateway-biotechnology)
* [https://www.crunchbase.com/organization/gateway-biotechnology](https://www.crunchbase.com/organization/gateway-biotechnology)